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Introduction: Ivacaftor, a cystic ﬁbrosis transmembrane regulator (CFTR) potentiator is currently
approved for use in individuals with class III gating mutations and the R117H mutation, a non-gating
mutation with residual functioning CFTR. Nevertheless, ivacaftor may also be effective in individuals
who have CF mutations giving rise to a residual functioning protein. However, aside from case reports
involving a single patient, little data exist on the use of ivacaftor in such individuals.
Methods: A real life pragmatic report wherein seven adults with mutations resulting in a CFTR with
residual function were prescribed ivacaftor. Four individuals with similar mutations acted as comparison.
We assessed lung function, body mass index, sweat chloride; the number of acute respiratory exacer-
bations and health related quality of life.
Results: Patients with residual functioning CFTR showed signiﬁcant improvement or stabilization in all
parameters up to 3 years following the start of ivacaftor. Those with similar mutations and who did not
receive ivacaftor worsened.
Conclusion: We report the use of ivacaftor in seven adults with various Class IV and V non-gating CFTR
mutation with residual functioning protein and we demonstrate improvement in several clinical
parameters.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cystic ﬁbrosis (CF) is caused by mutations in the CF trans-
membrane conductance regulator (CFTR) gene resulting in
impaired transport of chloride ion across cell membranes. CF mu-
tations are generally grouped into six classes based on whether the
defect impacts production, trafﬁcking, function or stability of the
CFTR protein. Ivacaftor, a CFTR potentiator [1] (Vertex, Boston, MA)
was initially approved for CF patients with class III mutations, also
known as gating mutations. In a landmark study, the administra-
tion of ivacaftor to people with CF and at least one copy of G551D,
the most common gating mutation, produced improvement in
FEV1 and body mass index (BMI) as well as a decrease in sweat
chloride [2]. Further studies on other non-G551D gating mutations
extended the use of Ivacaftor to individuals with other class III
mutations [3].
The use of ivacaftor was further extended when a trial examined
its efﬁcacy in subjects with R117H, a class IV mutation with partialLtd. This is an open access article uchannel activity. This study demonstrated a 5% increase in FEV1 in
those over 18 years of age, who presumably have more advanced
disease. Improvements were also noted in sweat chloride, BMI and
in the Cystic Fibrosis Questionnaire Revised (CFQ-R) [4]. Based on
these results, ivacaftor was then approved for use in people with CF
and the R117H mutation [5], but not in those with other CFTR
mutations. Prior studies of ivacaftor, albeit in vitro, demonstrated
considerable improvements in chloride transport in non-gating
CFTR mutations suggesting that ivacaftor could beneﬁt CF in-
dividuals with mutations other than those involving strictly gating
defects [6]. Indeed, in a patient with the P67Lmutation, the beneﬁts
of ivacaftor were demonstrated [7]. To our knowledge, aside from
single case reports, there have been no publications on the use of
ivacaftor in CF patients who have mutation with residual func-
tioning protein (classes IV and V). We report the use of ivacaftor in
seven CF adults with various class IV and V mutations.2. Methods
All patients who were cared for at our adult CF center and who
had at least one CFTR mutation resulting in a protein with residualnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
pre ivacaftor 3 yrs post ivacaftor
)L/elo
m
m(
edirolh
Ctae
wS
0
20
40
60
80
100
Fig. 1. Sweat chloride was measured in 5 patients at baseline (pre-ivacaftor) and at 3
years on the drug.
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clusion in a treatment or non-treatment group was whether the
patients' health plan would approve payment for ivacaftor. Since
this drug is not currently approved for people with CF and muta-
tions with residual functioning protein, apart from the R117H
mutation [5]; its cost of approximately US$300,000/year renders it
prohibitive for patients to purchase on their own, or for the CF
center to supply it to them. In seven patients, the health insurance
carriers agreed to provide the drug. In four others, ivacaftor could
not be obtained, and these individuals served as non-treatment
comparisons. None of the patients included in this report had CF
related diabetes mellitus or CF related liver disease and all had si-
nus disease. Sweat chloride was measured in ﬁve patients who
received ivacaftor in our CFF-accredited institutional laboratory
using the pilocarpine iontophoresis method [8]. The mean of two
measurements performed at least one week apart was used. All
data were collected at visits when patients were in their usual state
of health, taking their usual maintenance medications and without
an acute CF exacerbation. We deﬁned an acute exacerbation as
decreased exercise tolerance with increased cough; increased
sputum; absence from school or work; decreased appetite and
increased adventitial sounds on lung examination [10,11]. Addi-
tionally, an acute exacerbation required the addition of new oral or
intravenous antibiotics to the patient's regimen. The study was
approved by the Northwell health system institutional review
board.
2.1. Statistical analysis
The program SPSS version 21 (IBM, Armonk, NY) was used for
analysis. Normally distributed results were expressed as mean ± sd
and comparison was made using the t-test. Non-normally distrib-
uted data were expressed as median (IQR) using the rank sum test
to determine signiﬁcance. We used the Department of Psychology
at the University of Miami Excel program to calculate CFQ-R scores
[9].
3. Results
All patients who received ivacaftor had been on the drug for at
least three years. Those who did not receive ivacaftor were also
followed for three years. We attempted to collect data one month
following administration of ivacaftor and every 3 months there-
after. Improvements in FEV1%predicted, BMI and CFQ-R and sweat
chloride were noted as early as one month following the admin-
istration of ivacaftor. Subsequently, we observed no further
improvement in any parameter. Because of this, and for the sake of
clarity, we show data at baseline and at 3 years.Table 1
Study population characteristics.
Patient Sex Age at diagnosis Age baseline Mutation
Ivacaftor #1 F 18 30 R347P/L1065P
#2 F 16 28 R347P/L1065P
#3 F 30 48 2789 þ 5G/R1066C
#4 M 12 28 S912X/D579G
#5 F 28 43 del F508/R352Q
#6 M 51 72 G542X/D1152H
#7 M 51 56 W1282X/D1152H
No therapy #8 F 65 72 del F508/D1152H
#9 F birth 34 del F508/R352Q
#10 F 28 56 del F508/R334W
#11 F 8 22 3849 þ 10KBC > T/3
Ps- Pseudomonas species (none were multi-drug resistant); MRSA- Methicillin-resistant
romobacter xylosoxidans; Sm- Stenotrophomonas. PS/PI ¼ pancreatic sufﬁcient/insufﬁcienAt three years following the administration of ivacaftor, %pre-
dicted FEV1 increased from a baseline value of 50 (27, 56) to 60 (33,
55), p < 0.05. In the 4 individuals who did not receive ivacaftor, the
%predicted FEV1 was 61 ± 15 at year 1 and 54 ± 14 at year 3. In-
dividuals who received ivacaftor had an increase in BMI from
19.5 ± 2 at baseline to 22.3 ± 3 at three years (p < 0.05), while the
group in which the drug could not be obtained, the BMI at baseline
was 22 ± 3 and 21 ± 3 at year three. Individuals who received
ivacaftor, demonstrated an increase in CFQ-R from 50 ± 5 at base-
line to 95 ± 5 (p < 0.05). In those not taking the drug, we found no
change (48 ± 6 to 50 ± 4). The number of acute respiratory exac-
erbations decreased from an average of 4.4 ± 2 exacerbations
annually to 2 ± 2 (p < 0.5) in the ivacaftor group. In thosewho could
not receive ivacaftor, the number of exacerbations was not statis-
tically different 4.6 ± 2 at baseline to 5.5 ± 3 at three years.
Table 1 demonstrates the characteristics of all patient. Fig. 1
demonstrates results on 5 patients who underwent sweat chlo-
ride measurements prior to and at 3 years following ivacaftor
administration.While the sweat chloride decreased in each patient,
Due to the small number of patients and the large variance in
baseline sweat chloride, we could not demonstrate statistical sig-
niﬁcance. Finally, we examined sputummicrobiology and found no
change. The bacteria present prior to administering ivacaftor were
present 3 years later.
4. Discussion
We demonstrate that the administration of ivacaftor to in-
dividuals with CF mutations that produce a CFTR proteinwith somePS/PI Micro-biology Baseline FEV1% Baseline sweat Cl
PS Ps 80 97
PS Ps, MRSA 74 95
PS Ac 34 65
PI Ps, MSSA 35 66
PS Sm 34 80
PS Ps 40 22
PS Ps, MSSA 65 33
PS MRSA 69 83
PS Sm 64 75
PS Ps 56 66
849 þ 10KBC > T PS Ps, MRSA 55 88
Staphylococcus Aureus; MSSA- Methicillin-sensitive Staphylococcus Aureus; Ac- Ach-
t.
S. Guigui et al. / Respiratory Medicine Case Reports 19 (2016) 193e195 195function resulted in improvement in the %predicted FEV1, BMI,
CFQ-R and a decrease in the number of acute exacerbations. We
also show a non-signiﬁcant decrease in the sweat chloride in 5
patients on ivacaftor. To our knowledge, this study includes the
largest number of CF patients with mutations resulting in a
partially functioning protein, and spans a wide range of mutations,
ages and disease severity. Furthermore, patients were followed for
up to three years on ivacaftor. The non-treatment group was also
followed for three years and included CF patients with similar age,
mutations and disease burden. In this group, the disease worsened.
We failed to detect changes in sputummicrobiology in our group of
patients who took ivacaftor. While we performed sputum micro-
biology, more sensitive techniques such as culture-independent
methods for characterizing bacteria, together with a molecular
phylogenetic approach, might reveal a different picture.
Interestingly, the Food and Drug Administration (FDA) did not
grant approval to Vertex for its supplemental NewDrug Application
(sNDA) to use ivacaftor in CF patients with residual function mu-
tations [12]. Vertex's sNDA application was based on preclinical
data and results from a Phase 2a trial. This study included 24 pa-
tients with 23 mutations. The study consisted of two, two-week
treatment cycles of ivacaftor followed by two treatment cycles of
placebo, or vice-versa. While ivacaftor increased %predicted FEV1
compared to placebo, the FDA determined that it cannot approve
the drug based on these ﬁndings alone. Our results support and
supplement these data. The patients in this report had some of the
twenty-three mutations included in the phase 2a trial: 2789þ5G-
> A (patient 3 who stabilized with ivacaftor), 3849 þ 10kbC- > T
(patient 11 who deteriorated without ivacaftor), D579G (patient 4
who improvedwith ivacaftor) and D1152H (patients 6 and 7 both of
whom improvedwith ivacaftor and patient 8 who could not receive
the drug and worsened).
Our report is not a controlled trial. It was neither blinded, nor
was it randomized. Consequently, this report is susceptible to bias
even thoughwe demonstrate statistically signiﬁcant improvements
in several important parameters. Wewere unable to randomize our
patients to treatment or non-treatment groups. Indeed, the pa-
tient's assignment depended on whether the insurance carrier
approved payment tor this medication or not. Nevertheless, this is a
real life, pragmatic report and provides strong evidence for the
potential beneﬁts of ivacaftor in these CF individuals. Additionally,
we report the largest group of CF patients (seven) with residual
function mutations to receive ivacaftor who were followed for
three years.
5. Conclusions
We report improvement in CF disease in seven individuals who
were followed for three years on ivacaftor compared to theirbaseline (pre-initiation of ivacaftor). These data provide evidence
supporting the possibility of beneﬁcial effects of CFTR potentiators
in people with CFTR mutations producing residual functioning
protein. While there appears to be a need for a randomized double
blinded trial using ivacaftor, the low number of CF patients with
these relevant genotypes makes such an undertaking challenging.
Nevertheless, our data support alternative trial designs for these
difﬁcult to study CF subpopulations.Conﬂict of interest
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